A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

The STEM Leadership Center, a Westchester County based nonprofit, in partnership with Regeneron Pharmaceuticals, Inc. and ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

Regeneron Pharmaceuticals (NASDAQ ... (SNY), which was primarily driven by the sale of Dupixent. While the New York-based company managed to beat the consensus estimates by $43 million, I want ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 12.37% on an annualized basis producing an average annual return of 24.38%. Currently, Regeneron ...

Regeneron Pharmaceuticals, Inc. discovers ... The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN ...

Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a 50 day moving average price of $714.37 and a two-hundred day moving average price of ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did ...